Shots:
- The approval is based on P-III trial evaluating efficacy & safety of Kyprolis + dexamethasone in 123 patients with RRMM who have received at least 2 prior therapies, including a proteasome inhibitor & an immunomodulatory agent
- Results: ORR (35.8%); m-PFS (5.6mos.) as assessed by IRC. Additionally, results showed that the efficacy & safety in Chinese patients who had received a median of 4 prior lines of therapy was generally consistent with that seen in the global studies
- BeiGene got the license for Kyprolis under its collaboration with Amgen. The approval marks the first approval of the therapy in China
Click here to read full press release/ article | Ref: BeiGene | Image: Forbes
The post BeiGene’s Kyprolis (carfilzomib) Receives NMPA’s Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma first appeared on PharmaShots.
